ClinicalTrials.gg
RecruitingNCT04898335TENDERUpdated May 24, 2021

Tendyne European Experience Registry

An observational study in Mitral Regurgitation, sponsored by LMU Klinikum. Recruiting at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-24.

Sponsored by LMU Klinikum · Observational

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.

Planned enrollment
14th of 33
400 · median 214
Started
2021
with 3 others
Observational
33 of 81
12 open now
Primary completion
2026-12
later than 12 of 31 live
Registered
62nd of 81
by date
Lead sponsor
3 of 81
LMU Klinikum

Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 14th largest by planned enrollment of the 33 observational ones that give a count, is one of 4 that started in 2021, is one of 33 observational ones, reaches primary completion later than 12 of the 31 other live ones, and was the 62nd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Mitral Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

TENDER is a multicenter, single-device, retrospective and prospective, observational study to assess safety and efficacy of the Tendyne Mitral Valve System in a real-world population.

Read the detailed description

Mitral regurgitation (MR) is a common disease and is associated with high morbidity and mortality if left untreated. Due to age and comorbidities, patients are often ineligible for surgical repair or replacement. Over the last years, transcatheter systems have been introduced as an alternative therapeutic approach. The Tendyne Mitral Valve System (Abbott Vascular, Roseville, Minnesota) is a transcatheter transapical, self-expanding valve prosthesis for mitral valve replacement. A recent study has proven safety and feasibilty of the system, leading to commercial approvement (CE mark). However, data on real world experience with the system are not available.

TENDER is a multicenter, single-device, retrospective and prospective, observational study. Objectives of the study are 1) to assess early outcomes, including safety and efficacy, in patients treated with the Tendyne Mitral Valve System for severe MR at 30 days, 2) to assess clinical outcomes in patients treated with the Tendyne Mitral Valve System for severe MR at 1 year and 3 year follow-up, and 3) to identify echocardiographic and CT-based anatomic predictors associated with outcomes.

03

Conditions studied

  • Mitral Regurgitation

Keywords

  • mitral regurgitation
  • Tendyne
  • transcatheter mitral valve replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

All consecutive patients undergoing Implantation of Tendyne Mitral Valve System at the participating centres.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated with the Tendyne Mitral Valve System for mitral valve disease in a commercial setting
  • Patients providing written in compliance with the protocol, the ICH-GCP and all national legal and regulatory requirements

Exclusion criteria

Exclusion Criteria:

  • Patients not providing written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Tendyne

    all patients treated with a Tendyne Mitral Valve System

    Device: Tendyne Mitral Valve System

Interventions

  • DeviceTendyne Mitral Valve System

    Tendyne Mitral Valve System for mitral valve disease in a commercial setting

06

What researchers measure

Primary outcomes

  1. Rate of procedural success

    Device success (structural and functional); absence of death, stroke, life-threatening bleeding, major vascular or cardiac structural complications, acute kidney injury, myocardial infarction, heart failure and valve-related dysfunction requiring repeat procedure

    Time frame: 30 days

Secondary outcomes

  1. Rate of peri-procedural myocardial infarction

    Myocardial infarction during the index procedure

    Time frame: 1 day

  2. Rate of conversion to open-heart surgery

    Conversion to open-heart surgery during the index procedure

    Time frame: 1 day

  3. Rate of cardiac tamponade

    Cardiac Tamponade during the index procedure

    Time frame: 1 day

  4. Rate of procedural mortality

    Death during the index procedure

    Time frame: 1 day

  5. Rate of technical success (cumulative endpoint according to MVARC)

    Absence of procedural mortality, successful access, delivery and retrieval of the delivery system, successful deployment and positioning, freedom from emergency surgery) Device success (according to MVARC): absence of procedural mortality or stroke, proper placement and positioning, freedom from unplaned procedure related to the device or access, continued safety and performance of the device (no structural or functional failure, no technical complications, reduction of MR ≤ 2+ and mitral valve gradient \< 5 mmHg)

    Time frame: 1 day

  6. Rate of device success (cumulative endpoint according to MVARC)

    Absence of procedural mortality or stroke, proper placement and positioning, freedom from unplaned procedure related to the device or access, continued safety and performance of the device (no structural or functional failure, no technical complications, reduction of MR ≤ 2+ and mitral valve gradient \< 5 mmHg)

    Time frame: 30 days, 1 year and 3 years

  7. New York Heart Association (NYHA) functional class

    class I - IV

    Time frame: 30 days, 1 year and 3 years

  8. 6-minute walk distance (6MWD)

    in m

    Time frame: 30 days, 1 year and 3 years

  9. BNP/NT-proBNP level

    in pg/ml

    Time frame: 30 days, 1 year and 3 years

  10. Mitral regurgitation severity grade

    grade 0/1+/2+/3+/4+

    Time frame: 30 days, 1 year and 3 years

  11. Left and right ventricular dimensions

    left/right ventricular end-diastolic/-systolic diameter (in mm)

    Time frame: 30 days, 1 year and 3 years

  12. Left ventricular function

    LVEF in percent

    Time frame: 30 days, 1 year and 3 years

  13. Right ventricular function

    TAPSE in mm

    Time frame: 30 days, 1 year and 3 years

  14. Pulmonary artery pressure

    in mmHg

    Time frame: 30 days, 1 year and 3 years

  15. Tricuspid regurgitation severity grade

    grade 1-5

    Time frame: 30 days, 1 year and 3 years

  16. Transprosthetic gradient

    in mmHg

    Time frame: 30 days, 1 year and 3 years

07

Study locations

23 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 68 months is above that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 24, 2021
StartActual
Apr 15, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
May 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04898335
Lead sponsor
LMU Klinikum
Responsible party
Prof. Dr. med. Jörg Hausleiter (Prof. Dr. med. Jörg Hausleiter, LMU Klinikum) — Principal investigator
First posted
May 24, 2021
Start date
Apr 15, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 24, 2021

Study contacts

Joerg Hausleiter, MD
Contact
joerg.hausleiter@med.uni-muenchen.de
0049894400 ext. 72360
Mirjam Wild, MD
Contact
mirjam.wild@insel.ch
Joerg Hausleiter, MD
principal investigator · LMU Klinikum Munich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion